A5040699244- Cancer Genomics and Diagnostics
- Intraperitoneal and Appendiceal Malignancies
- Epigenetics and DNA Methylation
- Genetic factors in colorectal cancer
- Pancreatic and Hepatic Oncology Research
- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Colorectal Cancer Screening and Detection
- Hepatocellular Carcinoma Treatment and Prognosis
- Appendicitis Diagnosis and Management
- Gastric Cancer Management and Outcomes
- RNA modifications and cancer
- Dietary Effects on Health
- Lung Cancer Treatments and Mutations
- Ovarian cancer diagnosis and treatment
- Hernia repair and management
Vrije Universiteit Amsterdam
2019-2023
Amsterdam University Medical Centers
2019-2022
Dutch Cancer Society
2022
Cancer Center Amsterdam
2022
Dutch Colorectal Cancer Group
2021
Amsterdam UMC Location Vrije Universiteit Amsterdam
2018
A significant proportion of colorectal cancer (CRC) patients develop peritoneal metastases (PM) in the course their disease. PMs are associated with a poor quality life, morbidity and dismal disease outcome. To improve care for this patient group, better understanding molecular characteristics CRC-PM is required. Here we present comprehensive characterization cohort 52 patients. This reveals that represent distinct CRC subtype, CMS4, but can be further divided three separate categories, each...
<h3>Importance</h3> To date, no randomized clinical trials have investigated perioperative systemic therapy relative to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) alone for resectable colorectal peritoneal metastases (CPM). <h3>Objective</h3> assess the feasibility safety of in patients with CPM response neoadjuvant treatment. <h3>Design, Setting, Participants</h3> An open-label, parallel-group phase 2 trial all 9 Dutch tertiary centers surgical treatment...
Background Urine poses an attractive non-invasive means for obtaining liquid biopsies oncological diagnostics. Especially molecular analysis on urinary DNA is a rapid growing field. However, optimal and practical storage conditions that result in preservation of DNA, particular hypermethylated (hmDNA), are yet to be determined. Aim To determine the most urine adequate hmDNA analysis. Methods yield use methylation was determined by quantitative specific PCR (qMSP) targeting ACTB RASSF1A genes...
Abstract Colorectal cancer (CRC) is the second leading cause for cancer-related death globally. Clinically, there an urgent need non-invasive CRC detection. This study assessed feasibility of detection by analysis tumor-derived methylated DNA fragments in urine. Urine samples, including both unfractioned and supernatant urine fractions, 92 patients 63 healthy volunteers were analyzed methylation levels 6 CRC-associated markers ( SEPT9 , TMEFF2 SDC2 NDRG4 VIM ALX4 ). Optimal marker panels...
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) may be curative for colorectal cancer patients with peritoneal metastases (PMs) but it has a high rate of morbidity. Accurate preoperative patient selection is therefore imperative, constrained by the limitations current imaging techniques. In this pilot study, we explored feasibility circulating tumor (ct) DNA analysis to select CRS-HIPEC. Thirty eligible CRS-HIPEC provided blood samples preoperatively during...
Circulating tumor (ct)DNA analysis is rapidly gaining acceptance as a diagnostic tool to guide clinical management of advanced non-small cell lung cancer (NSCLC). Clinically-actionable EGFR mutations can be detected in ctDNA before or after first-line EGFR-Tyrosine Kinase Inhibitor (TKI) treatment, but data are limited for patients with complex treatment history. This study aimed explore the feasibility testing setting NSCLC receiving osimertinib second third line EGFR-TKI.Twenty...
Lung cancer has the highest cancer-related mortality worldwide and earlier detection could improve outcomes. Urine circulating tumor DNA (ctDNA) represents a true non-invasive means for ambulant sample collection. In this prospective study, potential of urine perioperative non-metastatic non-small cell lung (NSCLC) using ctDNA methylation analysis is evaluated.Preoperative samples 46 surgical NSCLC patients 50 sex age-matched controls were analyzed NSCLC-associated markers CDO1, SOX17, TAC1,...
High levels of methylated DNA in urine represent an emerging biomarker for non-small cell lung cancer (NSCLC) detection and are the subject ongoing research. This study aimed to investigate circadian variation urinary cell-free (cfDNA) abundance methylation cancer-associated genes NSCLC patients. In this prospective 23 metastatic patients with active disease, were asked collect six samples during morning, afternoon, evening two subsequent days. Urinary cfDNA concentrations CDO1, SOX17, TAC1...